Gribero (Dabigatran Etexilate)

Gribero is indicated for several thrombo‑embolic conditions where anticoagulation is required.

• Prevention of stroke and systemic embolism in patients with non‑valvular atrial fibrillation.
• Treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE).
• Reduction of recurrence risk after initial DVT or PE therapy.
• Prophylaxis of DVT in patients undergoing orthopedic surgery such as total hip or knee replacement.

The safety profile of Gribero includes both frequent, less severe reactions and rare, potentially serious events.

Common

• Dyspepsia or stomach discomfort.
• Minor gastrointestinal bleeding (e.g., epistaxis, gum bleeding).
• Nausea.
• Headache.

Serious

• Major bleeding, including intracranial hemorrhage.
• Gastrointestinal perforation.
• Allergic reactions such as rash or angioedema.

When prescribing Gribero, clinicians consider several precautionary factors to minimize risk.

• Assess renal function; dose adjustment may be needed in impaired clearance.
• Evaluate bleeding risk, especially in patients with a history of hemorrhage.
• Use cautiously in elderly patients due to increased susceptibility to bleeding.
• Avoid in patients with active pathological bleeding or recent major surgery.
• Monitor for signs of thrombotic events if therapy is interrupted.
• Counsel patients on adherence, as missed doses can affect anticoagulant control.

Gribero can interact with other medicines, influencing its anticoagulant effect or bleeding risk.

Avoid

• Strong P‑glycoprotein (P‑gp) inhibitors such as ketoconazole, itraconazole, or ritonavir.
• Concurrent use with other anticoagulants (e.g., warfarin, heparin) unless specifically directed.

Use with caution

• Moderate P‑gp inhibitors like amiodarone, verapamil, or diltiazem.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) and antiplatelet agents (e.g., aspirin, clopidogrel).
• Antifungal agents (e.g., fluconazole) and certain antibiotics (e.g., rifampin).